PIK3CA and neoplasm: This may be attributed to the developing nature of the NCIS Developmental Therapeutic Unit over the trial period and a corresponding increase in the number of potential trial options available along with increasing access to approved biomarker-selected treatments such as alpelisib in PIK3CA hotspot mutated tumours.